CORTI, CHIARA
CORTI, CHIARA
Dipartimento di Oncologia ed Emato-Oncologia
Artificial intelligence as an adjunct tool for breast oncologists – are we there yet?
2023 S.I. I., M. Saad Menezes, C. Corti, A. Tan, I. Abuali, S. Tolaney
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fuca, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
2023 C. Valenza, G. Rizzo, M.I. Passalacqua, L. Boldrini, C. Corti, D. Trapani, G. Curigliano
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
2023 C. Corti, C. De Angelis, G. Bianchini, L. Malorni, M. Giuliano, E. Hamilton, R. Jeselsohn, K. Jhaveri, G. Curigliano, C. Criscitiello
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
2023 S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M.B. Giachetti, C. Sposetti, M.G. Razeti, B.T. Salimbeni, L. Boldrini, A.C. Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care
2023 C. Corti, M. Cobanaj, E.C. Dee, C. Criscitiello, S.M. Tolaney, L.A. Celi, G. Curigliano
High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study
2023 F. Conforti, L. Pala, G. Vivanet, C. Corti, C. Catania, D. Maiettini, G. Varano, B. Di Venosa, G. Curigliano, P. Salvini, R. Berardi, Z. Ballatore, T.M. De Pas
HER2-Low Breast Cancer: a New Subtype?
2023 C. Corti, F. Giugliano, E. Nicolò, P. Tarantino, C. Criscitiello, G. Curigliano
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
2023 F. Giugliano, A. Carnevale Schianca, C. Corti, M. Ivanova, N. Bianco, S. Dellapasqua, C. Criscitiello, N. Fusco, G. Curigliano, E. Munzone
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 G. Antonarelli, C. Corti, P. Tarantino, B.T. Salimbeni, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials
2023 G. Castellano, C. Corti, L. Boldrini, L. Gervaso, C. Criscitiello, G. Curigliano
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Future potential targets of antibody-drug conjugates in breast cancer
2023 C. Corti, L. Boscolo Bielo, A.C. Schianca, B.T. Salimbeni, C. Criscitiello, G. Curigliano
Broadening the scope of artificial intelligence in oncology
2023 R. Ravella, E.C. Dee, C. Corti, L.A. Celi, P. Iyengar
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
2023 G. Spitaleri, P. Trillo Aliaga, I. Attili, E. Del Signore, C. Corvaja, C. Corti, E. Crimini, A. Passaro, F. de Marinis
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis
2022 F. Giugliano, P.A. Zucali, G. Galli, Z. Ballatore, C. Corti, P.T. Aliaga, J. Uliano, G. Vivanet, G. Curigliano, F. Conforti, P. Queirolo, R. Berardi, S. Manglaviti, G. Apollonio, M. Perrino, F. Borea, F. D'Antonio, M.C. Garassino, T. De Pas
High-Dose Ifosfamide for advanced thymic epithelial tumors (TETs): a TYME network study
2022 G. Vivanet, C. Corti, F. Conforti, P. Zucali, M. Perrino, R. Berardi, Z. Ballatore, C. Catania, L. Pala, G. Curigliano, D. Maiettini, B. Di Venosa, T. De Pas
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population
2022 L. Mazzarella, F. Giugliano, E. Nicolo', E. Crimini, J. Uliano, C. Corti, P. D'Amico, P. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P. Giachetti, I. Minchella, C. Belli, A. Esposito, M. Locatelli, C. Criscitiello, G. Curigliano